Jade Bioscience Reports Preclinical Data For JADE301

Jade Biosciences announced preclinical data for JADE301, an investigational anti-IFN-Beta monoclonal antibody targeting dermatomyositis, a rare autoimmune disease associated with skin inflammation and muscle weakness. The update supports continued early-stage development, but no clinical efficacy, safety, financial, or regulatory details were disclosed.